

Research article

## Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation

Ana Ruigómez\*<sup>1</sup>, Saga Johansson<sup>2,3</sup>, Mari-Ann Wallander<sup>2,4</sup> and Luis Alberto García Rodríguez<sup>1</sup>

Address: <sup>1</sup>Centro Español de Investigación Farmacoepidemiológica (CEIFE), Spain, <sup>2</sup>AstraZeneca. Mölndal, Sweden, <sup>3</sup>Section of Preventive Cardiology, Göteborg University, Sweden and <sup>4</sup>Department of Public Health and Caring Science, Uppsala University, Sweden

E-mail: Ana Ruigómez\* - aruigomez@ceife.es; Saga Johansson - Saga.Johansson@astrazeneca.com; Mari-Ann Wallander - Mari-Ann.Wallander@astrazeneca.com; Luis Alberto García Rodríguez - lagarcia@ceife.es

\*Corresponding author

Published: 26 February 2002

Received: 16 November 2001

*BMC Cardiovascular Disorders* 2002, 2:5

Accepted: 26 February 2002

This article is available from: <http://www.biomedcentral.com/1471-2261/2/5>

© 2002 Ruigómez et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

**Objective:** To estimate the mortality rate of patients newly diagnosed with chronic atrial fibrillation (AF) and compare it with the one in the general population. To evaluate the role of co-morbidity and other factors on the risk of dying among AF patients.

**Methods:** We used the General Practice Research Database in the UK to perform a retrospective cohort study. We followed a cohort of chronic AF patients (N = 1,035) and an age and sex matched cohort of 5,000 subjects sampled from the general population. We used all deceased AF patients as cases (n = 234) and the remaining AF patients as controls to perform a nested case-control analysis. We estimated mortality risk associated with AF using Cox regression. We computed mortality relative risks using logistic regression among AF patients.

**Results:** During a mean follow-up of two years, 393 patients died in the general population cohort and 234 in the AF cohort. Adjusted relative risk of death in the cohort of AF was 2.5 (95%CI 2.1 – 3.0) compared to the general population. Among AF patients, mortality risk increased remarkably with advancing age. Smokers carried a relative risk of dying close to threefold. Ischaemic heart disease was the strongest clinical predictor of mortality with a RR of 3.0 (95% CI; 2.1–4.1). Current use of calcium channel blockers, warfarin and aspirin was associated with a decreased risk of mortality.

**Conclusions:** Chronic AF is an important determinant of increased mortality. Major risk factors for mortality in the AF cohort were age, smoking and cardiovascular co-morbidity, in particular ischaemic heart disease.

### Background

Atrial fibrillation (AF) is a common cardiovascular disease among adults associated with a substantial morbidity and increased mortality [1–3]. Incidence of AF increases markedly with advancing age [4,5], with an incidence rate of

less than 0.1 per 1,000 person years among subjects aged 40 to 49, rising to 8.6 among subjects aged 80–89 years. It has been recognised that AF is an important risk factor for all-cause mortality, mainly due to an increased risk of cardiovascular deaths [6,7].

Results from different studies report that patients with AF have a mortality rate about twice that of age- and sex-matched individuals without AF [8,9]. In the Framingham Heart study, the excess mortality associated with AF persisted after adjustment for the preexisting cardiovascular conditions [2]. Aging, diabetes, heart failure and myocardial infarction were found to be independent risk factors for cardiovascular mortality among patients with chronic AF [2,10]. However, the information on the impact of chronic AF on mortality in the general population is limited, and to the best of our knowledge no study with UK data has been published.

We therefore conducted a study on the mortality rate in a population-based cohort of patients newly diagnosed with permanent/chronic atrial fibrillation and compared it with the one in a general population cohort. We evaluated the role of co-morbidity, drug treatments and other factors on the risk of dying among AF patients.

### Materials and Methods

We used the General Practice Research Database (GPRD) in the UK to perform a population based cohort study. The GPRD contains prospectively collected medical information on about 3 million patients. This database has been used in multiple epidemiologic studies that have confirmed the completeness and validity of the recorded data [11–13]. We identified a total of 703,730 patients in the GPRD meeting the following conditions: 40–89 years old enrolled with a general practitioner for more than two years and a computerized prescription history of at least one year before January 1996. This was done to ensure that the patients have had at least one contact with the GP in the year prior to entering the study. Patients with a code for cancer (I CD 1400–2099) before January 1996 were omitted. From this source population we identified both study cohorts.

### Study cohorts

**AF cohort:** We identified patients aged 40–89 years with a first ever recorded diagnosis of permanent/chronic atrial fibrillation in 1996. The diagnosis was confirmed by the general practitioners (GPs) through a questionnaire, this process is describe in detailed in a previous study [4]. We requested the GPs to confirm whether the episode of chronic AF was the first ever and to provide information on diagnostic tests, procedures and aetiology of the AF (patient confidentiality was always preserved). We excluded patients classified by the GP as having paroxysmal AF, 1,035 were finally confirmed. **General Population cohort:** Using the same source population in which the AF patients were identified and applying the same eligibility criteria as for the AF cohort, we sampled an age and sex matched cohort of 5,000 individuals free of AF.

### Analysis

The two cohorts were followed up from date of first diagnosis of chronic AF (start date) and from a random date during 1996 in the general population cohort until the earliest of death, or end of follow-up (December 1999). Survival probability was computed in both cohorts and we estimated the relative risk of dying associated with AF using Cox proportional hazard regression to control for risk factors.

A nested case-control analysis was performed in the AF cohort to assess risk factors of death. We used all deceased AF patients as cases ( $n = 234$ ) and used their death date as index date. The remaining alive AF patients ( $n = 801$ ) were considered controls and we sampled a random date during their follow-up period that was used as their index date. Estimates of mortality risk and 95% confidence interval (CI) were computed using logistic regression. We collected recorded information on the following risk factors: smoking status, BMI, alcohol consumption, as well as prior history of heart failure (HF), ischaemic heart disease (IHD), cerebrovascular disease (CVD), hypertension and diabetes. We used both the information in the questionnaire and computerized files to ascertain the cause of death.

### Drug exposure definition


We extracted from computerized records information on drugs used to treat AF between start date and index date: diuretics, beta-blockers, ACE inhibitors, calcium channel blockers, digoxin, aspirin, warfarin, NSAIDs, and other anti-arrhythmic drugs (disopyramide, procainamide, quinidine, flecainide, propafenone and amiodarone). We defined current use when drug supply lasted until index date or ended in the previous month. We considered short-term use when duration was less than 3 months, and long-term use when duration was more than 3 months. Past use was considered when the end of the most recent prescription was more than one month before index date and non use when there was no drug use between start and index date.

### Results

During a mean follow-up of close to two years, 393 patients died in the general population cohort and 234 in the AF cohort. Patients with AF had a significantly lower survival than patients from the general population without AF (Figure 1). The increased mortality was already present in the early phase of follow-up. Half of the deaths in the AF cohort were related to ischaemic heart disease (IHD) or other cardiovascular diseases (45% of all cause mortality). In the general population cohort, these two causes accounted for 29% of all deaths (table 1). The relative risk of mortality among patients with chronic atrial fibrillation was 2.5 (95% CI 2.1–3.0) compared to the

general population after adjusting for co-morbidity and major clinical risk factors (table 2). This risk was 2.3 (95% CI 1.8–3.0) in men and 2.8 (95% CI 2.2–3.6) in women. When considering only cerebro- and cardio-vascular deaths (n= 306), the corresponding adjusted RR associated with chronic AF was 3.7 (95% CI 3.0–4.7).

Table 3 shows the effect of several factors on the mortality risk in the cohort of chronic AF patients. The mortality risk increased remarkably with advancing age. Smokers carried a relative risk of dying close to threefold. Diabetes, heart failure and cerebrovascular disease were all associated with estimates of RR between 1.5 and 2. Ischaemic heart disease was the strongest clinical predictor of mortality with a RR of 3.0 (95% CI; 2.1–4.1). We did not find any significant association between alcohol consumption and mortality. Overweight patients (BMI of 30 or more) had a relative risk of 0.5 (95%CI: 0.3–0.9) compared to subjects with a BMI between 22 and 25 after adjusting for age, sex, smoking and preexisting conditions.



**Figure 1**  
Kaplan-Meier survival curve for chronic atrial fibrillation and general population cohorts. (mean follow-up time 22 months -SD 12.9; range: 0.5–47 months).

**Table 1: Distribution of causes of death in the cohort of chronic atrial fibrillation patients and the general population**

	General Population Cohort		AF Cohort	
	N = 393	%	N = 234	%
<b>Causes of death</b>				
Ischaemic heart disease (IHD)	70	17.8	61	21.1
Other cardiovascular no IHD *	42	10.7	56	24
Cerebrovascular disease†	44	11.2	33	14.1
Cancer	64	16.3	27	11.5
Other diseases‡	107	27.2	48	20.5
Unknown	66	16.8	9	3.8

\* Includes heart failure, heart valvular and rhythm disorders and vascular diseases (PVD, aneurism, pulmonary embolism). †includes ischaemic and haemorrhagic cerebrovascular accidents. ‡Includes respiratory, gastrointestinal, liver, renal diseases, infection and trauma.

**Table 2: Incidence rate and relative risk of death in the cohort of chronic atrial fibrillation patients compared to the general population**

	General Population Cohort	AF Cohort
Person-years	9261	1898
Deaths	393	234
Mortality rate/100 p-years (95% CI)	4.2 (3.8–4.7)	12.3 (10.8–14.0)
Relative Risk * (95% CI)	1	2.5 (2.1 – 3.0)

\* Relative risk estimated by Cox regression including age, sex, smoking, diabetes, heart failure, 'Ischaemic heart disease, hypertension, cerebrovascular disease

**Table 3: Risk of mortality associated with different risk factors among chronic atrial fibrillation patients.**

	<b>Cases</b> n = 234	(%)	<b>Controls</b> n = 801	(%)	<b>Odds Ratio*</b> (95% CI)
<b>Sex</b>					
Males	115	(49.1)	372	(53.6)	1
Females	119	(50.9)	429	(46.4)	0.9 (0.6–1.3)
<b>Age</b>					
40–59 years	4	(1.7)	67	(8.4)	1
60–69 years	19	(8.1)	136	(17.0)	1.9 (0.6–5.9)
70–79 years	93	(39.7)	325	(40.6)	4.0 (1.4 – 11.7)
80–89 years	118	(50.4)	273	(34.1)	6.0 (2.0–17.6)
<b>Smoking status</b>					
Never smoker	108	(46.2)	486	(60.7)	1
Smoker	59	(25.2)	127	(15.9)	2.6 (1.7–4.0)
Ex-smoker	28	(12.0)	84	(10.5)	1.6 (0.9–2.7)
Unknown	39	(16.7)	104	(13.0)	1.7 (1.0–2.9)
<b>BMI (weight /height<sup>2</sup>)</b>					
<22	30	(12.8)	82	(10.2)	1.0 (0.6–1.9)
22–24.9	49	(20.9)	138	(17.2)	1
25–30	60	(25.6)	227	(28.3)	0.8 (0.5–1.3)
+30	20	(8.5)	131	(16.4)	0.5 (0.3–0.9)
Unknown	75	(32.1)	223	(27.8)	0.9 (0.5–1.5)
<b>Prior co-morbidity</b>					
Diabetes	30	(12.8)	59	(7.4)	2.1 (1.3–3.6)
Heart Failure	137	(58.5)	271	(33.8)	1.9 (1.4–2.7)
Ischemic heart disease	127	(54.3)	206	(25.7)	3.0 (2.1 – 4.2)
Hypertension	104	(44.4)	355	(44.3)	0.9 (0.7–1.3)
Cerebrovascular disease	73	(31.2)	159	(19.9)	1.5 (1.1 – 2.2)

\*Estimates of risk are adjusted for all variables included in the table using logistic regression.

Current use of calcium channel blockers, aspirin and warfarin were associated with a significant reduced risk of all cause mortality (Table 4). When we separated current use into short and long term use (less than 3 months of use versus more), we observed that the reduced risk of mortality was mainly among long-term users of these drugs. Users of calcium channel blockers for more than 3 months carried a risk of 0.4 (95%CI 0.2–0.7), the respective estimates for warfarin long term users was 0.4 (95%CI 0.3–0.8) and for aspirin (RR: 0.6; 95%CI 0.4–0.9). Current use of NSAIDs was associated with an increased mortality (RR of 1.8; 95% CI 1.0–3.2).

The estimates of mortality risk for all risk factors evaluated only changed marginally when we restricted the analysis to cardiovascular deaths that included IHD, heart failure, other cardiovascular and cerebrovascular diseases (data not shown).

## Discussion

We found that permanent AF is an important independent predictor of mortality. AF patients carried an all cause mortality risk close to 3 times greater than the one in an

age and sex matched general population cohort. We are not aware of other studies that have evaluated the impact of chronic AF on mortality in a UK general population setting.

Some specific characteristics of the study need to be considered. Firstly, the ascertainment of AF in general population is problematic, as some of the cases can remain undetected if these episodes are brief mild [5]. We only studied chronic AF and by using a general practice setting we tried to ensure that even less severe cases of AF could be identified. There is always room for missclassification between paroxysmal and chronic AF. We tried to minimise this potential bias by reviewing all computerized histories of AF patients and finally requesting the GP to confirm the diagnosis of chronic AF. The higher probability of detecting more severe or symptomatic cases -those that contact the GP- may lead to a slight overestimation of mortality associated with AF, and could explain the higher mortality rate found in our study compared to studies using screening methods for case ascertainment. Secondly, we could not ascertain the underlying cause of death in 12% of the subjects and this proportion was higher

**Table 4: Risk of mortality associated with use of cardiovascular treatment drugs in the AF cohort**

	<b>Cases</b> n = 234	(%)	<b>Controls</b> n = 801	(%)	<b>Odds Ratio*</b> (95% CI)
<b>Diuretics</b>					
Non use	46	(19.7)	237	(29.6)	1
Current use	135	(57.7)	419	(52.3)	1.1 (0.6–1.7)
Past use	53	(22.6)	145	(18.1)	1.1 (0.6–1.9)
<b>Beta Blockers</b>					
Non use	169	(72.2)	561	(70.0)	1
Current use	13	(5.6)	87	(10.9)	0.8 (0.4–1.6)
Past use	52	(22.2)	153	(19.1)	1.0 (0.6–1.6)
<b>ACE inhibitors</b>					
Non use	137	(58.5)	524	(65.4)	1
Current use	70	(29.9)	208	(26.0)	0.8 (0.5–1.3)
Past use	27	(11.5)	69	(8.6)	1.0 (0.5–1.8)
<b>Calcium Channel Blockers</b>					
Non use	165	(70.5)	560	(69.9)	1
Current	18	(7.7)	125	(15.6)	0.4 (0.2–0.7)
Past use	51	(21.8)	116	(14.5)	1.2 (0.7–1.8)
<b>Digoxin</b>					
Non use	51	(21.8)	191	(23.8)	1
Current	143	(61.1)	496	(61.9)	0.9 (0.6–1.4)
Past use	40	(17.1)	114	(14.2)	1.0 (0.5–1.7)
<b>Amiodarone †</b>					
Non use	212	(90.6)	726	(90.6)	1
Current	14	(6.0)	44	(5.5)	1.3 (0.6–2.8)
Past use	8	(3.4)	31	(3.9)	0.8 (0.3–2.2)
<b>Warfarin</b>					
Non use	174	(74.4)	503	(62.8)	1
Current	37	(15.8)	226	(28.2)	0.5 (0.3–0.8)
Past use	23	(9.8)	72	(9.0)	1.0 (0.5–1.8)
<b>Aspirin</b>					
Non use	109	(46.6)	407	(50.8)	1
Current	72	(30.8)	239	(29.8)	0.6 (0.4–0.9)
Past use	53	(22.6)	155	(19.4)	0.8 (0.5–1.2)

\*Estimates are adjusted for age, sex, smoking, diabetes, heart failure, 'Ischaemic heart disease, hypertension, cerebrovascular disease and all the drugs groups in the table, using logistic regression. †There was no use of other antiarrhythmic drugs (disopyramide, procainamide, quinidine, flecainide and propafenone).

among the general population cohort than in than AF patients cohort. Atrial fibrillation patients have a higher consultation rate with their GP than the general population and as a result these patients tend to have more information recorded on minor morbidity and causes of death than patients from the general population. Third, we had a considerable level of missing information on BMI, mainly due to unrecorded data on height not routinely measured in elderly and other risk factors.

Estimates of mortality risk associated with AF have been reported to be around two for all cause mortality, and between two and twelve for cardiovascular mortality [14]. Our corresponding estimate for the latter end-point was

close to four while our findings of all cause mortality risk associated with chronic AF were in the higher range of those from previous studies. The small difference can partly be explained by the different methods used in the identification of AF patients, the inclusion of different types of AF (chronic versus all AF) and the distinct ascertainment of causes of death [2,3,9,14]. Among patients with at least one other cardiovascular diagnosis, mortality risk was approximately 20% higher in patients with AF compared to those without AF [9]. In the Framingham Heart Study, the authors reported that the excess mortality attributed to atrial fibrillation (chronic, paroxysmal or flutter) was independent of preexisting cardiovascular conditions associated with atrial fibrillation. Their estimate of mortality

associated with atrial fibrillation was 1.5 in men and 1.9 in women after adjusting for other cardiovascular co-morbidity [2]. In our study we only assessed the risk among chronic AF patients, and found higher estimates of risk for both men (RR = 2.3) and women (RR = 2.8) after taking into account preexisting diseases commonly associated with AF, such as IHD or HF. It could be argued that chronic forms of AF carry a greater mortality risk than paroxysmal AF and flutter, and this could explain the higher estimates observed in our study.

In agreement with previous studies, we confirmed that the major risk factors for mortality in AF patients are old age, smoking and cardiovascular co-morbidity [2,10,14]. We identified the same risk factors and with a similar magnitude of risk when restricting the outcome to specific cardiovascular mortality. Another study found that the increased risk for all cause mortality in AF patients was largely due to an increased mortality risk due to ventricular failure [7]. In our study, we observed that half of all deaths were due to IHD and other cardiovascular diseases in the AF cohort. A previous review by Alpert et al [15] reported that the mortality risk was age dependent and presence of HF at the time of onset of AF was an important prognostic factor. In our study, we found that coexisting heart failure carried a two fold increased risk of all cause mortality and ischaemic heart disease a three fold increase.

The use of anti-arrhythmic drugs and digoxin for atrial fibrillation among patients with coexisting cardiovascular morbidity has been controversial [16–18]. An increased risk of cardiac mortality has been reported among AF patients with a history of congestive heart failure receiving anti-arrhythmic drugs compared to patients not treated [16,19]. Other studies have concluded that anti-arrhythmic drug therapy in AF patients does not translate into an improvement in mortality and have suggested that class I anti-arrhythmic drugs should be avoided in AF patients with advanced heart failure [20]. We found no significant difference in mortality risk among those treated and not treated with anti-arrhythmic drugs such as amiodarone, beta blockers or digoxin after adjusting for cardiovascular disease and other drug treatment. Though we found some evidence for a protective effect with some drug treatments, one should be cautious in interpreting these results due to the observational design of our study and the relative statistical variability.

In our study, obesity (BMI>30) was associated with a 50 % reduced risk of all cause mortality. The Longitudinal Study of Aging reported a reduced mortality in obese elderly people after adjustment for other factors [21]. We could not find any published study that examined this as-

sociation among AF patients and further studies are warranted to confirm this finding.

### Competing interests

This study was supported by a research grant from Astra-Zeneca.

### Acknowledgements

We thank the staff at GPRD, and the participating general practitioners for their collaboration. We also thank the Boston Collaborative Drug Surveillance Program (BCDSP) for providing access to the database.

### References

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: **Prevalence of diagnosed atrial fibrillation in adults. National Implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) Study.** *JAMA* 2001, **285**:2370-2375
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: **Impact of atrial fibrillation on the risk of death: The Framingham Heart Study.** *Circulation* 1998, **98**(10):946-952
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE: **The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up study.** *Am J Med* 1995, **98**(5):476-84
4. Ruigómez A, Johansson S, Wallander MA, García Rodríguez LA: **The incidence of chronic atrial fibrillation in general practice and its treatment pattern.** *J Clin Epidemiol* 2002, **55**:358-363
5. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: **Independent risks factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study.** *JAMA* 1994, **271**:840-844
6. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D: **New-onset atrial fibrillation: sex differences in presentation, treatment and outcome.** *Circulation* 2001, **103**(19):2365-70
7. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Warclawiw MA, Stevenson LW: **Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.** *J Am Coll Cardiol* 1998, **32**(3):695-703
8. Laupacis A, Cuddy TE: **Prognosis of individuals with atrial fibrillation.** *Can J Cardiol* 1996, **12**:14A-16A
9. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB: **Impact of atrial fibrillation on mortality, stroke, and medical costs.** *Arch Intern Med* 1998, **158**(3):229-234
10. Scardi S, Mazzone C, Pandullo C, Goldstein D, Di Lenarda A, Chersevani D: **Mortality and cause of death in patients with chronic non-rheumatic atrial fibrillation after two years follow-up.** *G Ital Cardiol* 1999, **29**(6):637-46
11. Jick H, Jick SS, Derby LE: **Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.** *BMJ* 1991, **302**:766-768
12. Jick H, Terris BZ, Derby LE, Jick SS: **Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom.** *Pharmacoepidemiol Drug Safety* 1992, **1**:347-349
13. García Rodríguez LA, Pérez Gutthann S: **Use of the UK General Practice Research Database for pharmacoepidemiology.** *Br J Clin Pharmacol* 1998, **45**:419-425
14. Domanski MJ: **The epidemiology of atrial fibrillation.** *Coronary Artery Disease* 1995, **6**:95-100
15. Alpert JS, Petersen P, Godtfriksen J: **Atrial fibrillation: Natural history, complications and management.** *Ann Rev Med* 1988, **39**:41-52
16. Flacker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: **Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.** *J Am Coll Cardiol* 1992, **20**(3):527-32
17. Falk RH, Leavitt JI: **Digoxin for atrial fibrillation: a drug whose time has gone?** *Ann Intern Med* 1991, **114**(7):573-5

18. Jung F, DiMarco JP: **Treatment strategies for atrial fibrillation.** *Am J Med* 1998, **104(3)**:272-86
19. Maisel WH, Kuntz KM, Reimold SC, Lee TH, Antman EM, Friedman PL, Stevenson WG: **Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital.** *Ann Int Med* 1997, **127(4)**:281-4
20. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimie A, Walden JA, Tillisch JH: **Improving survival for patients with atrial fibrillation and advanced heart failure.** *J Am Coll Cardiol* 1996, **28(6)**:1458-63
21. Grabowski DC, Ellis JE: **High body mass index does not predict mortality in older people: analysis of the Longitudinal Study of Aging.** *J Am Geriatr Soc* 2001, **49**:968-79

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

 **BioMedcentral.com**

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)